Medical Disease After Abdominal Solid Organ Transplantation and the Risk of Solid and Hematologic Malignant Tumor After Transplantation

  • Maria Cristina MorelliEmail author


Solid organ transplantation is the treatment of choice for selected patients with end-stage organ insufficiency. Currently, the survival of patients after kidney and liver transplantation exceeds respectively 80 and 70% after 5 years, associated in the majority of cases with a good quality of life. While in the early postoperative period the main causes of morbidity and mortality are related to the primary organ dysfunction, surgical complications or postoperative infection, in the long term they are mainly related to the emergence of disorders linked to immunosuppressive therapy side effects or to primary disease recurrence. Monitoring immunosuppressive drug blood levels is a key point in the management of patients after solid organ transplantation in order to minimize the potential adverse effects. However, careful management of potentially modifiable risk factors such as metabolic syndrome, cardiovascular diseases and renal insufficiency may improve long-term survival.


Metabolic Syndrome Liver Transplantation Chronic Renal Failure Mycophenolate Mofetil Calcineurin Inhibitor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Pfitzmann R, Nüssler N, Hippler-Benscheidt M, Neuhaus R, Neuhaus P. Long-term results after liver transplantation. Transpl Int. 2008;21(3):234–46.CrossRefPubMedGoogle Scholar
  2. 2.
    Westbrook RH, Yeoman AD, Agarwal K, Aluvihare V, Mieli- Vergani G, Dhawan A, et al. An evaluation of mortality in adults and children who have survived in excess of 5 and 10 years since liver transplantation [abstract]. Liver Transpl. 2009;15 suppl 7:S101.Google Scholar
  3. 3.
    Meier-Kriesche HU, et al. Immunosuppression: evolution in practice and trends, 1994–2004. Am J Transplant. 2006;6:1111–31.CrossRefPubMedGoogle Scholar
  4. 4.
    Kasiske B, Guijarro C, Massy Z, Wiederkehr M, Ma J. Cardiovascular disease after renal transplantation. J Am Soc Nephrol. 1996;7:158–65.PubMedGoogle Scholar
  5. 5.
    Grundy S, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735–52.CrossRefPubMedGoogle Scholar
  6. 6.
    Tellez-Avila F, Sanchez-Avila F, Garcia-Saenz-de-Socolia M, Chavez-Tapia NC, Granco-Gusman AM, Lopez-Arce G, et al. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol. 2008;14:4771–5.PubMedCentralCrossRefPubMedGoogle Scholar
  7. 7.
    Soveri I, Abedini S, Holdaas H, Jardine A, Eriksson N, Fellström B. Graft loss risk in renal transplant recipients with metabolic syndrome: subgroup analyses of the ALERT trial. J Nephrol. 2012;25(02):245–54.CrossRefPubMedGoogle Scholar
  8. 8.
    Anastacio LR, Diniz KG, Ribeiro HS, Ferreira LG, Lima AS, Correia MI, Vilela EG. Prospective evaluation of metabolic syndrome and its components among long-term liver recipients. Liver Int. 2014;11:5–8.Google Scholar
  9. 9.
    Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, McQueen M, Budaj A, Pais P, Varigos J, Lisheng L, INTERHEART Study Investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364(9438):937–52.CrossRefPubMedGoogle Scholar
  10. 10.
    Poonawala A, Nair S, Thuluvath P. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000;32:689–92.CrossRefPubMedGoogle Scholar
  11. 11.
    Leonarda J, Heimbachb JK, Malinchocc M, Watta K, Charlton M. The impact of obesity on long-term outcomes in liver transplant recipients—results of the NIDDK liver transplant database. Am J Transplant. 2008;8:667–72.CrossRefGoogle Scholar
  12. 12.
    Hoogeveen EK, Aalten J, Rothman KJ, et al. Effect of obesity on the outcome of kidney transplantation: a 20-year follow-up. Transplantation. 2011;91:869–74.CrossRefPubMedGoogle Scholar
  13. 13.
    Massy ZA. Hyperlipidemia and cardiovascular disease after organ transplantation. Transplantation. 2001;72:S13–5.CrossRefPubMedGoogle Scholar
  14. 14.
    Stegall MD, Everson G, Schroter G, et al. Metabolic complications after liver transplantation. Diabetes, hypercholesterolaemia, hypertension, and obesity. Transplantation. 1995;60:1057.PubMedGoogle Scholar
  15. 15.
    Duclos A, Flachner IM, Faiman C, et al. Post-transplant diabetes mellitus: risk reduction strategies in the elderly. Drugs Aging. 2006;23:781–93.CrossRefPubMedGoogle Scholar
  16. 16.
    Heisel O, et al. New onset diabetes mellitus in patients receiving calcineurin inhibitors: a systematic review and meta-analysis. Am J Transplant. 2004;4:583–95.CrossRefPubMedGoogle Scholar
  17. 17.
    Sharif A, Moore RH, Baboolal K. The use of oral glucose tolerance tests to risk stratify for new-onset diabetes after transplantation: an underdiagnosed phenomenon. Transplantation. 2006;82:1667–72.CrossRefPubMedGoogle Scholar
  18. 18.
    Madhwal R, Atreja A, Albeldawdi M, Lopez R, Post A, Costa MA. Is liver transplantation a risk factor for cardiovascular disease? a meta-analysis of observational studies. Liver Transpl. 2012;18:1140–6.CrossRefPubMedGoogle Scholar
  19. 19.
    Beyer N, Aadahl M, Strange B, Kirkegaard P, Hansen BA, Mohr T, Kjaer M. Improved physical performance after orthotopic liver transplantation. Liver Transpl Surg. 1999;5:301–9.CrossRefPubMedGoogle Scholar
  20. 20.
    Krasnoff JB, Vintro AQ, Ascher NL, Bass NM, Paul SM, Dodd MJ, Painter PL. A randomized trial of exercise and dietary counseling after liver transplantation. Am J Transplant. 2006;6:1896–905.CrossRefPubMedGoogle Scholar
  21. 21.
    Painter P, Krasnoff J, Paul SM, Ascher NL. Physical activity and health-related quality of life in liver transplant recipients. Liver Transpl. 2001;7:213–9.CrossRefPubMedGoogle Scholar
  22. 22.
    Sennesael JJ, Lamote JG, Violet I, Tasse S, Verbeelen DL. Divergent effects of calcium channel and angiotensin converting enzyme block- ade on glomerulotubular function in cyclosporine-treated renal allograft recipients. Am J Kidney Dis. 1996;27(5):701–8.CrossRefPubMedGoogle Scholar
  23. 23.
    Cross NB, Webster AC, Masson P, O’connell PJ, Craig JC. Antihypertensives for kidney transplant recipients: systematic review and meta-analysis of randomized controlled trials. Transplantation. 2009;88(1):7–18.CrossRefPubMedGoogle Scholar
  24. 24.
    Grazi IF, et al. Statins and solid organ transplantation. Curr Pharm Des. 2006;12:4771–83.CrossRefGoogle Scholar
  25. 25.
    Ojo AO, Held PJ, Port KF, Robert A, Wolfe MS, Leichtman AB, Young EW, Arndorfer J, Christensen L, Merion RM. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med. 2003;349:931–40.CrossRefPubMedGoogle Scholar
  26. 26.
    Textor SC, Burnett Jr JC, Romero JC, Canzanello VJ, Taler SJ, Wiesner R, Porayko M, Krom R, Gores G, Hay E. Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation. Kidney Int. 1995;47(5):1426–33.CrossRefPubMedGoogle Scholar
  27. 27.
    Eckhoff DE, McGuire B, Sellers M, Contreras J, Frenette L, Young C, Hudson S, Bynon JS. The safety and efficacy of a two-dose daclizumab (zenapax) induction therapy in liver transplant recipients. Transplantation. 2000;69(9):1867–72.CrossRefPubMedGoogle Scholar
  28. 28.
    Kornberg A, Kupper B, Hommann M, Scheele J. Introduction of MMF in conjunction with stepwise reduction of calcineurin inhibitor in stable liver transplant patients with renal dysfunction. Int Immunopharmacol. 2005;5:141–6.CrossRefPubMedGoogle Scholar
  29. 29.
    Biselli M, Vitale G, Gramenzi A, et al. Two year mycophenolate mofetil plus low-dose calcineurin inhibitor for renal dysfunction after liver transplant. Clin Transplant. 2009;23:191–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Castroagudin JF, Molina E, Romero R, et al. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction. Liver Transpl. 2009;15:1792–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Penn I. Cancers complicating organ transplantation. N Engl J Med. 1990;323(25):1767–9.CrossRefPubMedGoogle Scholar
  32. 32.
    Pruthi J, Medkiff KA, Esrason KT, Donovan JA, Yoshida EM, Erb SR, Steinbrecher UP, Fong TL. Analysis of causes of death in liver transplant recipients who survived more than 3 years. Liver Transpl. 2001;7:811.CrossRefPubMedGoogle Scholar
  33. 33.
    Haagsma EB, Hagens VE, Schaapveld M, van den Berg AP, de Vries EG, Klompmaker IJ, et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol. 2001;34:84–91.CrossRefPubMedGoogle Scholar
  34. 34.
    Goh A, Vathsala A. Native renal cysts and dialysis duration are risk factors for renal cell carcinoma in renal transplant recipients. Am J Transplant. 2011;11:86–92.CrossRefPubMedGoogle Scholar
  35. 35.
    Herrero JI. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl. 2009;15:S90–4.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2015

Authors and Affiliations

  1. 1.UO Internal Medicine for the Treatment of Severe Organ InsufficiencyOrgan Insufficiency and TransplantationBolognaItaly

Personalised recommendations